Glaucoma

Glaucoma is a neurodegenerative disease characterized by progressive damage to the optic nerve, leading to characteristic visual field defects and, if untreated, blindness. The primary pathological hallmark is the irreversible loss of retinal ganglion cells and their axons, which constitute the optic nerve. While the exact etiology is multifactorial, elevated intraocular pressure (IOP) is the most significant modifiable risk factor.

IOP is determined by the balance between aqueous humor production by the ciliary body and its outflow through the trabecular meshwork and uveoscleral pathways. In open-angle glaucoma, the trabecular meshwork's drainage capacity is compromised, leading to a gradual increase in IOP. This sustained pressure can mechanically stress the optic nerve head, causing axonal damage and cell death.

However, it's crucial to note that glaucoma can also occur with normal IOP (normal-tension glaucoma), suggesting other factors like vascular dysregulation, impaired axonal transport, or genetic predispositions play a role in optic nerve susceptibility.

The prevalence of glaucoma escalates significantly with age, affecting a substantial portion of the elderly population. Globally, it is a leading cause of irreversible blindness. Epidemiological studies reveal significant variations in incidence and prevalence across different populations and ethnicities.

For instance, open-angle glaucoma is more common in individuals of African descent, often presenting at a younger age and with more advanced disease. Conversely, angle-closure glaucoma, characterized by a sudden blockage of the anterior chamber angle, is more prevalent in individuals of East Asian and Inuit descent and tends to affect women more frequently. Other critical risk factors include a positive family history, indicating a genetic predisposition; myopia (nearsightedness); diabetes; hypertension; and the long-term use of corticosteroid medications.

Understanding these diverse risk factors allows for targeted screening and preventative strategies.

Glaucoma is broadly categorized based on the state of the anterior chamber angle. Open-angle glaucoma (OAG) encompasses conditions where the angle is anatomically open, but outflow resistance is increased, typically at the level of the trabecular meshwork. This leads to a slow, insidious rise in IOP.

Primary open-angle glaucoma (POAG) is the most common form. In contrast, angle-closure glaucoma (ACG) occurs when the iris obstructs the trabecular meshwork, leading to a rapid and significant elevation in IOP. This can manifest as acute angle-closure glaucoma (AACG), a medical emergency characterized by severe eye pain, blurred vision, halos, headache, and nausea, or chronic angle-closure glaucoma (CACG), which may progress more subtly.

The distinction is critical for management, as ACG requires prompt intervention to relieve the pressure and prevent catastrophic vision loss.

The cornerstone of glaucoma management is to reduce IOP to a level that prevents or slows optic nerve damage. Pharmacological therapy, primarily through topical eye drops, is the first line of treatment. These medications work by either decreasing aqueous humor production (e.g., beta-blockers, alpha-agonists) or enhancing its outflow (e.g., prostaglandin analogs, miotics). Laser therapy, such as selective laser trabeculoplasty (SLT) for OAG or laser peripheral iridotomy (LPI) for ACG, offers a less invasive option to improve fluid drainage.

Surgical interventions, including trabeculectomy and glaucoma drainage device implantation, are reserved for cases where medical and laser treatments are insufficient. Emerging research is also exploring neuroprotective strategies and regenerative therapies to potentially repair or preserve optic nerve function, representing the future frontier in glaucoma care.